BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 34502319)

  • 1. A Multiplex CRISPR-Screen Identifies PLA2G4A as Prognostic Marker and Druggable Target for HOXA9 and MEIS1 Dependent AML.
    Hassan JJ; Lieske A; Dörpmund N; Klatt D; Hoffmann D; Kleppa MJ; Kustikova OS; Stahlhut M; Schwarzer A; Schambach A; Maetzig T
    Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502319
    [No Abstract]   [Full Text] [Related]  

  • 2. MicroRNA-708 is a novel regulator of the Hoxa9 program in myeloid cells.
    Schneider E; Pochert N; Ruess C; MacPhee L; Escano L; Miller C; Krowiorz K; Delsing Malmberg E; Heravi-Moussavi A; Lorzadeh A; Ashouri A; Grasedieck S; Sperb N; Kumar Kopparapu P; Iben S; Staffas A; Xiang P; Rösler R; Kanduri M; Larsson E; Fogelstrand L; Döhner H; Döhner K; Wiese S; Hirst M; Keith Humphries R; Palmqvist L; Kuchenbauer F; Rouhi A
    Leukemia; 2020 May; 34(5):1253-1265. PubMed ID: 31768018
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conditionally immortalised leukaemia initiating cells co-expressing Hoxa9/Meis1 demonstrate microenvironmental adaptation properties ex vivo while maintaining myelomonocytic memory.
    Stahlhut M; Ha TC; Takmakova E; Morgan MA; Schwarzer A; Schaudien D; Eder M; Schambach A; Kustikova OS
    Sci Rep; 2021 Mar; 11(1):5294. PubMed ID: 33674652
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PBX3 and MEIS1 Cooperate in Hematopoietic Cells to Drive Acute Myeloid Leukemias Characterized by a Core Transcriptome of the MLL-Rearranged Disease.
    Li Z; Chen P; Su R; Hu C; Li Y; Elkahloun AG; Zuo Z; Gurbuxani S; Arnovitz S; Weng H; Wang Y; Li S; Huang H; Neilly MB; Wang GG; Jiang X; Liu PP; Jin J; Chen J
    Cancer Res; 2016 Feb; 76(3):619-29. PubMed ID: 26747896
    [TBL] [Abstract][Full Text] [Related]  

  • 5. p27kip1 maintains a subset of leukemia stem cells in the quiescent state in murine MLL-leukemia.
    Zhang J; Seet CS; Sun C; Li J; You D; Volk A; Breslin P; Li X; Wei W; Qian Z; Zeleznik-Le NJ; Zhang Z; Zhang J
    Mol Oncol; 2013 Dec; 7(6):1069-82. PubMed ID: 23988911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Upregulation of Flt3 is a passive event in Hoxa9/Meis1-induced acute myeloid leukemia in mice.
    Staffas A; Arabanian LS; Wei SY; Jansson A; Ståhlman S; Johansson P; Fogelstrand L; Cammenga J; Kuchenbauer F; Palmqvist L
    Oncogene; 2017 Mar; 36(11):1516-1524. PubMed ID: 27617578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The endothelin receptor type A is a downstream target of Hoxa9 and Meis1 in acute myeloid leukemia.
    Arabanian LS; Johansson P; Staffas A; Nilsson T; Rouhi A; Fogelstrand L; Palmqvist L
    Leuk Res; 2018 Dec; 75():61-68. PubMed ID: 30384975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tip60 activates Hoxa9 and Meis1 expression through acetylation of H2A.Z, promoting MLL-AF10 and MLL-ENL acute myeloid leukemia.
    Yamagata K; Shino M; Aikawa Y; Fujita S; Kitabayashi I
    Leukemia; 2021 Oct; 35(10):2840-2853. PubMed ID: 33967269
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hif-1α and Hif-2α synergize to suppress AML development but are dispensable for disease maintenance.
    Vukovic M; Guitart AV; Sepulveda C; Villacreces A; O'Duibhir E; Panagopoulou TI; Ivens A; Menendez-Gonzalez J; Iglesias JM; Allen L; Glykofrydis F; Subramani C; Armesilla-Diaz A; Post AE; Schaak K; Gezer D; So CW; Holyoake TL; Wood A; O'Carroll D; Ratcliffe PJ; Kranc KR
    J Exp Med; 2015 Dec; 212(13):2223-34. PubMed ID: 26642852
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Wang W; Li H; Huang M; Wang X; Li W; Qian X; Jing L
    Open Biol; 2022 Oct; 12(10):220172. PubMed ID: 36285442
    [No Abstract]   [Full Text] [Related]  

  • 11. PBX3 is essential for leukemia stem cell maintenance in MLL-rearranged leukemia.
    Guo H; Chu Y; Wang L; Chen X; Chen Y; Cheng H; Zhang L; Zhou Y; Yang FC; Cheng T; Xu M; Zhang X; Zhou J; Yuan W
    Int J Cancer; 2017 Jul; 141(2):324-335. PubMed ID: 28411381
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Bai H; Zhou M; Zeng M; Han L
    DNA Cell Biol; 2020 Apr; 39(4):700-708. PubMed ID: 32077754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frequent co-expression of the HOXA9 and MEIS1 homeobox genes in human myeloid leukemias.
    Lawrence HJ; Rozenfeld S; Cruz C; Matsukuma K; Kwong A; Kömüves L; Buchberg AM; Largman C
    Leukemia; 1999 Dec; 13(12):1993-9. PubMed ID: 10602420
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Flt3 is dispensable to the Hoxa9/Meis1 leukemogenic cooperation.
    Morgado E; Albouhair S; Lavau C
    Blood; 2007 May; 109(9):4020-2. PubMed ID: 17202314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A pro B cell population forms the apex of the leukemic hierarchy in Hoxa9/Meis1-dependent AML.
    Lieske A; Agyeman-Duah E; Selich A; Dörpmund N; Talbot SR; Schambach A; Maetzig T
    Leukemia; 2023 Jan; 37(1):79-90. PubMed ID: 36517672
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Entospletinib in Combination with Induction Chemotherapy in Previously Untreated Acute Myeloid Leukemia: Response and Predictive Significance of
    Walker AR; Byrd JC; Blachly JS; Bhatnagar B; Mims AS; Orwick S; Lin TL; Crosswell HE; Zhang D; Minden MD; Munugalavadla V; Long L; Liu J; Pan Y; Oellerich T; Serve H; Rao AV; Blum WG
    Clin Cancer Res; 2020 Nov; 26(22):5852-5859. PubMed ID: 32820015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HOXA9 is required for survival in human MLL-rearranged acute leukemias.
    Faber J; Krivtsov AV; Stubbs MC; Wright R; Davis TN; van den Heuvel-Eibrink M; Zwaan CM; Kung AL; Armstrong SA
    Blood; 2009 Mar; 113(11):2375-85. PubMed ID: 19056693
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Persistent transactivation by meis1 replaces hox function in myeloid leukemogenesis models: evidence for co-occupancy of meis1-pbx and hox-pbx complexes on promoters of leukemia-associated genes.
    Wang GG; Pasillas MP; Kamps MP
    Mol Cell Biol; 2006 May; 26(10):3902-16. PubMed ID: 16648484
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MOZ is critical for the development of MOZ/MLL fusion-induced leukemia through regulation of Hoxa9/Meis1 expression.
    Katsumoto T; Ogawara Y; Yamagata K; Aikawa Y; Goitsuka R; Nakamura T; Kitabayashi I
    Blood Adv; 2022 Oct; 6(19):5527-5537. PubMed ID: 35947126
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MLL fusion protein-driven AML is selectively inhibited by targeted disruption of the MLL-PAFc interaction.
    Muntean AG; Chen W; Jones M; Granowicz EM; Maillard I; Hess JL
    Blood; 2013 Sep; 122(11):1914-22. PubMed ID: 23900238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.